PAG
PTGX icon

Private Advisor Group’s Protagonist Therapeutics PTGX Stock Holding History

Private Advisor Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-219
Closed -$4K – 2962
2020
Q2 		$4K Buy
+219
New +$2.75K ﹤0.01% 3350

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Private Advisor Group's PTGX Position: Q3 2020 in Review

Private Advisor Group sold out of Protagonist Therapeutics (PTGX) in Q3 2020, closing a stake of 219 shares — an estimated $4K sold.

Private Advisor Group first reported a position in PTGX in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 92 funds tracked by Wall St. Rank hold PTGX as of Q3 2020.

  • Private Advisor Group reported no remaining Protagonist Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 219 Protagonist Therapeutics shares in Q3 2020, an estimated $4K.
  • Private Advisor Group first reported a position in Protagonist Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Protagonist Therapeutics position peaked at $4K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.